• 1
    Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 453944.
  • 2
    NCCN (2009) Small Cell Lung Cancer. In: NCCN Clinical Practice Guidelines in Oncology V.2.2009. MS-1.
  • 3
    Murray N, Coy P, Pater JL et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993; 11: 33644.
  • 4
    Dowell JE. Small cell lung cancer: are we making progress? Am J Med Sci 2010; 339: 6876.
  • 5
    Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008; 83: 35567.
  • 6
    Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997; 15: 893900.
  • 7
    Bremnes RM, Sundstrom S, Aasebø U et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 2003; 39: 30313.
  • 8
    Hermes A, Waschki B, Gatzemeier U, Reck M. Characteristics, treatment patterns and outcomes of patients with small cell lung cancer–a retrospective single institution analysis. Lung Cancer 2011; 71: 3636.
  • 9
    Hermes A, Gatzemeier U, Waschki B, Reck M. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – a retrospective single institution analysis. Respir Med 2010; 104: 193742.
  • 10
    Li J, Dai CH, Chen P et al. Survival and prognostic factors in small cell lung cancer. Med Oncol 2010; 27: 7381.
  • 11
    Chen J, Jiang R, Garces YI et al. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer 2010; 67: 2216.
  • 12
    Videtic GM, Stitt LW, Dar AR et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003; 21: 15449.
  • 13
    Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology 1992; 3: 614.
  • 14
    Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. Int J Epidemiol 2007; 36: 104859.
  • 15
    Zhao H, Gu J, Xu H et al. [Meta-analysis of the relationship between passive smoking population in China and lung cancer]. Zhongguo Fei Ai Za Zhi 2010; 13: 61723. [In Chinese.
  • 16
    Allan SG, Stewart ME, Love S, Cornbleet MA, Smyth JF, Leonard RC. Prognosis at presentation of small cell carcinoma of the lung. Eur J Cancer 1990; 26: 7035.
  • 17
    Wolf M, Holle R, Hans K, Drings P, Havemann K. Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer 1991; 63: 98692.
  • 18
    Ludbrook JJ, Truong PT, MacNeil MV et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis. Int J Radiat Oncol Biol Phys 2003; 55: 132130.
  • 19
    Janssen-Heijnen ML, Maas HA, van de Schans SA, Coebergh JW, Groen HJ. Chemotherapy in elderly small-cell lung cancer patients: yes we can, but should we do it? Ann Oncol 2011; 22: 8216.
  • 20
    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990; 8: 156374.
  • 21
    Sagman U, Feld R, Evans WK et al. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oncol 1991; 9: 95461.
  • 22
    Pedersen LM, Milman N. Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996; 9: 182630.
  • 23
    Aoe K, Hiraki A, Ueoka H et al. Thrombocytosis as a useful prognostic indicator in patients with lung cancer. Respiration 2004; 71: 1703.
  • 24
    Green DL, Karpatkin S. Effect of cancer on platelets. Cancer Treat Res 2009; 148: 1730.
  • 25
    Ferrigno D, Buccheri G, Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 2001; 17: 66773.
  • 26
    Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 221421.
  • 27
    Aoe K, Hiraki A, Maeda T et al. Serum hemoglobin level determined at the first presentation is a poor prognostic indicator in patients with lung cancer. Intern Med 2005; 44: 8004.
  • 28
    Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Impact of preoperative hemoglobin level on survival of non-small cell lung cancer patients. Anticancer Res 2008; 28: 194750.
  • 29
    Blackwell K, Gascón P, Sigounas G, Jolliffe L. rHuEPO and improved treatment outcomes: potential modes of action. Oncologist 2004; 9 (Suppl. 5): 417.
  • 30
    Tas F, Aydiner A, Topuz E, Camlica H, Saip P, Eralp Y. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer. Acta Oncol 1999; 38: 10115.
  • 31
    Hochstenbag MM, Twijnstra A, Wilmink JT, Wouters EF, ten Velde GP. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol 2000; 48: 2438.
  • 32
    Seute T, Leffers P, ten Velde GP, Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 2004; 100: 8016.
  • 33
    Aupérin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341: 47684.
  • 34
    Meert AP, Paesmans M, Berghmans T et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 2001; 1: 5.
  • 35
    Paumier A, Cuenca X, Le Péchoux C. Prophylactic cranial irradiation in lung cancer. Cancer Treat Rev 2011; 37: 2615.
  • 36
    Giaccone G, Dalesio O, McVie GJ et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1993; 11: 123040.
  • 37
    Spiro SG, Souhami RL, Geddes DM et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 1989; 59: 57883.
  • 38
    Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials. Cancer 2005; 104: 26507.
  • 39
    Rossi A, Garassino MC, Cinquini M et al. Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010; 70: 11928.
  • 40
    Arriagada R, Pignon JP, Ihde DC et al. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients. Anticancer Res 1994; 14: 3335.
  • 41
    Fried DB, Morris DE, Poole C et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004; 22: 483745.
  • 42
    De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006; 24: 105763.
  • 43
    Oze I, Hotta K, Kiura K et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS ONE 2009; 4: e7835.